Clinical and biological predictors of progression-free survival (PFS) and overall survival (OS) in patients (pts) with advanced non-small-cell lung cancer (NSCLC) treated by erlotinib in the ERMETIC cohort Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010
Progression-free survival with first line treatment as prognostic factor of treatment success in subsequent lines in lung adenocarcinoma patients – who´s the „good responder“? Source: Virtual Congress 2021 – Therapy of lung cancer Year: 2021
Improved overall survival after early recurrence of lung cancer following the introduction of CT-based follow-up for patients initially treated with curative intent by (chemo)radiotherapy (CRT). Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
The analysis of lung cancer patients (LCP) survival during one-year period after diagnosing of disease Source: Eur Respir J 2006; 28: Suppl. 50, 88s Year: 2006
Clinical factors of long-term survival in patients with advanced lung cancer Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Long-term survival in lung cancer after surgery: is gender a prognostic factor? Source: Eur Respir J 2001; 18: Suppl. 33, 229s Year: 2001
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient Source: Eur Respir J 2015; 46: 280-282 Year: 2015
Improved overall survival after late recurrence of lung cancer following the introduction of CT-based follow-up for patients treated with curative intent Source: International Congress 2018 – Lung cancer: from early diagnosis to modern monitoring strategies Year: 2018
Trends in drug costs and overall survival in patients diagnosed with metastatic non-small cell lung cancer (NSCLC) Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019
Rates of treatment response and median survival in advanced non small cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 302s Year: 2004
Determining values of prognostic factors with patients with NSCLC based on two years survival Source: Annual Congress 2007 - Lung neoplasms Year: 2007
The survival in elderly patients after resection of lung cancer Source: Annual Congress 2008 - Congenital lung lesions and emphysema; lung cancer surgery Year: 2008
Importance of CYFRA-21 in estimation of survival of patients with NSCLC Source: Eur Respir J 2006; 28: Suppl. 50, 85s Year: 2006
Tumour metabolic-flow difference as a potential predictor of survival in non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Staging of lung cancer Year: 2010
Is gender a prognostic factor in long term survival non-small cell lung cancer? Source: Eur Respir J 2002; 20: Suppl. 38, 185s Year: 2002
Epidemiological and clinical predictors of survival during the first year of the treatment in non-small cell lung cancer patients Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009
Impact on recurrence and long-term survival Source: Annual Congress 2004 - Impact of neoadjuvant treatments on morbidity and oncological outcome of patients with NSCLC Year: 2004
Limited role of Ki-67 in lung carcinoid tumor patients predicting overall short-term survival,A single institution experience Source: International Congress 2018 – Lung cancer: novel prognostic markers and scores Year: 2018
Genomic signatures as predictors of progression free and overall survival Source: Annual Congress 2013 –Biological signatures in thoracic oncology Year: 2013
Concurrent chemoradiation in stage III NSCLC: High eligilbility and high rates of overall and progression-free survival with acceptable toxicity Source: Annual Congress 2013 –Lung cancer resection and radiotherapy and thoracic oncology late breaking abstracts Year: 2013